Clinical Characteristics for the Relationship between Type-2 XXXX and @entity73 : A Cross-Sectional Study.

@entity1 @entity6 @entity2204 @entity73 @entity2690 @entity413 @entity2449
We explored the potential differences in cognitive status, lipid and @entity413 metabolism, @entity2204 alleles and imaging between @entity6 and non- @entity6 subjects. 83 subjects with normal cognitive function and 114 mild @entity73 @entity1 were divided into four groups by history of @entity6 . General demographics was collected from all @entity1 followed by MRI scan, biochemical examinations and a series of neuropsychological tests. Student's t test, multiple regressions and one-way ANOVA were applied to investigate the differences between groups. Comparing @entity6 @entity1 with non- @entity6 subjects in the mild @entity73 group, we found several decreased items in recall of three words in MMSE (p=0.020), AVLT and SCWT (p<0.050). The multiple linear regression revealed that two-hour @entity413 level (B= -0.255, p<0.001) and fasting @entity2690 (B= -0.466, p=0.001) had negative effects on the score of MMSE. In addition, @entity6 @entity1 treated with insulin and other @entity6 medication performed better in part of the AVLT (p<0.050) compared to @entity1 with insulin treatment or oral antidiabetic medication only. @entity1 with @entity2449 medication had a better memory outcome compared to @entity1 with sulphonylurea medication in the AVLT long delay free recall (p =0.010). These findings show that @entity1 of mild @entity73 with @entity6 have a worse outcome in attention, information processing speed and memory compared to non- @entity6 @entity1 . Higher two-hour @entity413 level and @entity2690 level may be risk factors for severe @entity73 in @entity6 @entity1 . The results of this study also suggest that medication may have effects on cognitive function.
